Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,649 restricted stock units (RSUs) to four newly hired employees as of June 30, 2026. The awards were made under the 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU vests over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued service.

News Market Reaction – KPTI

+0.52%

1 alert

+0.52% Session close to close

+6.5% Peak Tracked

$216.43M Market Cap

0.1x Rel. Volume

In the Jul 2 session, KPTI gained 0.52%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.5% during that session.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a modest 1,649 RSU inducement grant vesting over three years for four new ...

Analysis

This announcement details a modest 1,649 RSU inducement grant vesting over three years for four new hires. It builds on recent equity-based compensation activity; investors may watch cumulative dilution and any further use of the effective resale registration.

Key Figures

Inducement RSUs: 1,649 RSUs Employees granted: 4 employees Vesting period: 3 years +1 more

4 metrics

Inducement RSUs 1,649 RSUs Aggregate grant to four new employees on June 30, 2026

Employees granted 4 employees Recipients of inducement RSU awards

Vesting period 3 years RSU vesting duration from Grant Date

Annual vesting rate 33 1/3% per year Each of three consecutive anniversaries of Grant Date

Historical Context

5 past events · Latest: Jun 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 03	KOL webcast	Neutral	+0.8%	Announcement of Cantor-hosted webcast with endometrial cancer key opinion leader.
Jun 02	Phase 3 data	Positive	-6.0%	Late‑breaking SENTRY myelofibrosis data selected for oral EHA 2026 slot.
Jun 02	Phase 3 data	Neutral	-6.0%	ASCO 2026 SENTRY results with strong SVR35 but missed symptom endpoint.
Jun 01	Inducement grant	Neutral	-6.0%	Prior single-employee inducement RSU grant under Nasdaq Rule 5635(c)(4).
Jun 01	Investor call	Positive	+7.9%	Investor call to discuss Phase 3 SENTRY trial following ASCO presentation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has triggered large, sometimes opposite, price reactions, especially around major Phase 3 data and investor events.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

4 terms

restricted stock units financial

"the Company granted an aggregate of 1,649 restricted stock units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"1,649 restricted stock units (RSUs) to four newly-hired employees"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of June 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO^® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO^® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302814036.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What inducement RSU grants did Karyopharm Therapeutics (KPTI) announce on July 1, 2026?

Karyopharm Therapeutics announced inducement grants totaling 1,649 RSUs to four new employees. According to Karyopharm, these were granted on June 30, 2026 under its 2022 Inducement Stock Incentive Plan as material inducements to accept employment.

How do the new Karyopharm (KPTI) inducement RSUs vest for employees?

The new Karyopharm inducement RSUs vest over three years. According to Karyopharm, 33 1/3% of each RSU award vests on each of the three consecutive anniversaries of the June 30, 2026 grant date, subject to continued service.

Why were Karyopharm (KPTI) RSUs granted under Nasdaq Listing Rule 5635(c)(4)?

Karyopharm granted these RSUs as inducements material to employment under Nasdaq Listing Rule 5635(c)(4). According to Karyopharm, the awards were issued outside shareholder-approved plans specifically to attract four newly hired employees to join the company.

How many new employees received Karyopharm Therapeutics (KPTI) inducement RSUs in June 2026?

Four newly hired employees received Karyopharm inducement RSUs in June 2026. According to Karyopharm, the total grant comprised 1,649 restricted stock units, awarded on June 30, 2026 as part of the company’s 2022 Inducement Stock Incentive Plan.

What employment conditions affect vesting of the June 30, 2026 Karyopharm (KPTI) RSU grants?

Vesting of the June 30, 2026 RSU grants depends on continued service. According to Karyopharm, each employee must remain employed by, or continue as another service provider to, the company through each applicable vesting date for shares to vest.